With a growing body of research supporting its efficacy, GLP-1 offers hope for those seeking sustainable and effective weight loss solutions
Potential areas of expansion include: Cardiovascular outcomes: A dedicated CVOT, if not already required as a post-marketing commitment, would evaluate whether orforglipron reduces MACE in patients with established cardiovascular disease or high cardiovascular risk, following the precedent set by the SELECT trial for semaglutide
doi:10.1007/s10840-017-0267-1 Wit AL and Boyden PA
Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al
Ob und in welchem Ausma Nebenwirkungen auftreten, ist individuell und hngt von verschiedenen Faktoren ab, wie dem Gesundheitszustand, der aktuellen Dosis und mglicher Unvertrglichkeiten
Several studies have reported that autophagy prevents RGC death in glaucoma animal models such as optic nerve transection and IOP elevation 24,25